Atuka will be exhibiting at the Society for Neuroscience Global Connectome: A Virtual Event which will be held from the 11th-13th January 2021. Please stop by our virtual booth to find out more about Atuka and the services that we offer in Parkinson’s disease, chemistry, drug development, cognitive disorders, biodistribution and primate services. See here for more information on this event.
Atuka will be exhibiting at the Alzheimer’s Association International Conference® 2020, July 27-31 on their cutting edge, virtual platform. The conference is free, so please register and stop by our virtual booth to find out more about Atuka and the services that we offer in Parkinson’s disease, chemistry, drug development, cognitive disorders, biodistribution and primate services.
Atuka Inc. and Ulysses Neuroscience Ltd., an Irish-based R&D organization, have entered a strategic partnership to co-market and combine expertise in biomarkers analysis and animal models to advance translational medicine in Parkinson’s Disease.
Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We provide cutting-edge, rodent and non-human primate models (both toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, both motor (e.g. parkinsonism and dyskinesia) and non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers non-GLP toxicity, biodistribution, medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics and diagnostics.
Ulysses Neuroscience has research platforms dedicated to: i) preclinical analysis of cognitive/behavioural alterations and neurophysiological recording in rodents, with a capacity in zebrafish under development; ii) preclinical/clinical biomarker analysis (synaptic plasticity and cytoskeletal dynamics) of proteins and nucleic acids in biological fluids and post-mortem tissues; iii) clinical trials for cognitive and behavioural assessments and sampling of biological fluids.
Dr. James Koprich, CSO of Atuka added, “Focusing on translatable biomarkers of both disease progression and target engagement will prove powerful in defining meaningful endpoints for preclinical and clinical trial designs. Together with Ulysses Neuroscience, we can work to validate the animal models in this important space and use these platforms in efficacy testing paradigms.”
Dr. Michael Hill, CEO of Atuka concluded, “We look forward to working with Ulysses Neuroscience and are confident our complimentary capabilities will enhance the studies we offer to our clients. In particular, combining Atuka’s expertise in animal models of Parkinson’s disease and Ulysses Neuroscience’s capabilities in assessment of translationally relevant biomarkers, is an exciting prospect.”
Dr. Massimiliano (Max) Bianchi, President & CEO of Ulysses Neuroscience said, “We are enthusiastic about working together with Atuka, a world leader CRO providing the most advanced and translational animal models of Parkinson’s Disease applied to both rodents and non-human primates. Ulysses Neuroscience will integrate analysis of central and peripheral (i.e. fluids) translational relevant biomarkers in these models for which the pharmaceutical industry has an urgent need in order to advance their drug discovery projects into the clinic”
Dr. Charlotte Callaghan, CSO & Patient Insight Manager of Ulysses Neuroscience continues, “Synaptic pathology is a key feature of neurodegenerative disease, including Parkinson’s Disease. Identification and analysis of markers of synaptic plasticity in peripheral fluids (blood plasma and CSF) in animal models of disease which are confirmed in the patient population has high translational value. Further, modification of these biomarkers by tool compounds in animal models will rapidly advance the drug discovery pipeline in industry and ultimately into the clinic”
|Dr. Michael Hill, CO-founder and CEO: firstname.lastname@example.org|
|Dr. James Koprich, CSO: email@example.com|
|Ulysses Neuroscience contacts|
|Dr. Massimiliano Bianchi, Founder / President & CEO: firstname.lastname@example.org|
|Dr. Charlotte Callaghan, CSO: email@example.com|
Atuka will be presenting at the 8th Annual Neurodegenerative Drug Development Summit, February 25-27 in Boston, USA. For more information on the meeting see here.
At the meeting, Atuka is also hosting a workshop on February 25, entitled “Navigating the Preclinical Drug Development Space”. Details on the workshop can be found here.
Atuka will be exhibiting at the Gene Therapy for Neurological Disorders conference, December 10-12 in Boston, USA. For more information on the services that Atuka can provide in this area see here.
For more information on the meeting go to www.gtxn-summit.com.
Atuka will be exhibiting at Neuroscience 2019, October 19-23 in Chicago, USA. Please drop by at booth 1945 and find out more about Atuka and the services that we offer in Parkinson’s disease, chemistry, drug development, cognitive disorders, biodistribution and primate services.
Dr Jonathan Brotchie will attend the Gordon Research Conference on Cannabinoid Function in the CNS on 21st-26th July in Barcelona, Spain. Abide Therapeutics and Atuka will present a poster entitled “The selective monoacylglycerol lipase inhibitor ABD-101970 reduces L-DOPA-induced dyskinesia in MPTP-lesioned macaques” at the meeting.
More information on the conference can be found here
Atuka will be exhibiting at the Alzheimer’s Association International Conference in Los Angeles, USA on the 14th – 17th July 2019. Please drop by booth #826 and find out more about Atuka and the services that we offer in Parkinson’s disease, cognitive disorders, biodistribution and chemistry.
More information on the meeting can be found here
Atuka will be exhibiting at the 5th World Parkinson Congress in Kyoto, Japan on the 4th – 7th June 2019. Please drop by booth #618 and find out more about Atuka and the services that we offer in Parkinson’s disease, cognitive disorders, biodistribution and chemistry.
More information on the meeting can be found here